Avalon GloboCare Corp
ALBT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.26M
Close$
$-0.26
218.5% downside
Current Fair Value
218.5% downsideOvervalued by 218.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $5.26 Million |
|---|---|
| Enterprise Value | $5.37 Million |
| Earnings per Share | $-5.64 |
| Beta | -0.03 |
| Outstanding Shares | 15,792,440 |
Return
| Return on Equity | -80.76% |
|---|---|
| Return on Assets | -55.25% |
| Return on Invested Capital | -127.10% |
Valuation & Multiples
| P/E Ratio | -0.12 |
|---|---|
| PEG | 0.14 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 15.32 |
| Enterprise Value to EBIT | -0.42 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.70%▼ 1.36% |
|---|---|
| Total Invested | $171,025▼ 38.98% |
| Investors Holding | 23▲ 3.00% |
About Avalon GloboCare Corp
7 employees
CEO: Meng Li
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 rela...